{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-006012","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2022-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.319142+00:00","generated_at":"2026-06-26T05:25:12.845276+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Nkarta to host April 25 conference call to discuss Phase 1 data for NKX101 and NKX019","bullets":["Conference call scheduled for April 25, 2022 at 8:00 a.m. ET to review preliminary clinical data.","NKX101 and NKX019 are engineered NK cell therapy candidates in ongoing Phase 1 trials.","Leading investigators from the two clinical trials will join management for the discussion.","Webcast and accompanying slides available on Nkarta’s website with replay for ~4 weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-006012","json":"https://secwatch.observer/filing/0000950170-22-006012.json","markdown":"https://secwatch.observer/filing/0000950170-22-006012.md","text":"https://secwatch.observer/filing/0000950170-22-006012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022006012/0000950170-22-006012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022006012/nktx-20220422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T05:25:12.845276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}